Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for ION582 in Angelman Syndrome. The expected timing is based on the latest available company guidance and may change.
REVEAL trial: 5/16/24- Positive HALOS Ph1/2a data. 7/22/24- Result reported. 11/6/24- Positive EOP2 w/ FDA. 6/11/25- First patient dosed in REVEAL Ph3 trial. Completion of enrollment in 2026. 01/11/26:- REVEAL Ph3 ION582 enrollment expected complete 2026; pivotal data readout in 2027. 07/06/26:- REVEAL Cohort 1 enrollment complete. Cohort 2 completes Q3 2026; topline H2 2027. CHAMPION Ph3 starts by Year-End 2026.
Verification
Confirm timing and program details against the company announcement or filing.